Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: Pharmacokinetics and therapeutic range

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 91, Issue 3, 1997, Pages 322-327

  Winstanley, Peter ^a,b   Watkins, William ^a,b   Muhia, David ^a   Szwandt, Simon ^b   Amukoye, Evans ^a   Marsh, Kevin ^a,c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chemotherapy; Children; Chlorcycloguanil; Chlorproguanil dapsone; Malaria; Pharmacokinetics; Plasmodium falciparum

Indexed keywords

ALBUMIN; CHLORCYCLOGUANIL; CHLORPROGUANIL; DAPSONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HUMAN; INFANT; MALARIA FALCIPARUM; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD;

PLASMODIUM FALCIPARUM;

EID: 0030925154     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(97)90093-6     Document Type: Article

References (30)

1. Björkman, A. & Phillips-Howard, P. A. (1991). Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bulletin of the World Health Organization, 69, 297-304.
2. Bloland, P. B., Lackritz, E., Kazembe, P., Were J. B. O., Steketee, R. & Campbell, C. C. (1993). Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy. Journal of Infectious Diseases, 167, 932-937.
3. Carr, K., Oates, J. A., Nies, A. S. & Woosley, R. L. (1978). Simultaneous analysis of dapsone and monoacetyl dapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. British Journal of Clinical Pharmacology, 6, 421-427.
4. Dollery, C. (editor) (1991). Dapsone. Therapeutic Drugs. Edinburgh etc.: Churchill Livingstone, pp. D11-D17.
5. Edstein, M. D. & Veenendaal, J. R. (1987). Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine® administration. Transactions of the Royal Society of Tropical Medicine and Hygiene, 81, 136-139.
6. Edstein, M. D., Rieckmann, K. H. & Veenendaal, J. R. (1990). Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim®) in man. British Journal of Clinical Pharmacology, 30, 259-265.
7. Foster, S. D. (1991). Pricing, distribution and use of antimalarial drugs. Bulletin of the World Health Organization, 69, 349-363.
8. Helsby, N. A., Ward, S. A., Howells, R. E. & Breckenridge, A. M. (1990). In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450MP) enzyme. British Journal of Clinical Pharmacology, 30, 287-291.
9. Jones, C. & Ovenell, S. M. (1979). Determination of plasmsa concentrations of dapsone, mono-acetyl dapsone and pyrimethamine in human subjects dosed with Maloprim®. Journal of Chromatography, 163, 179-185.
10. May, D. G., Porter, J. A., Uetrecht, J. P., Wilkinson, G. R. & Branch, R. A. (1990). The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clinical Pharmacology and Therapeutics, 48, 619-627.
11. Mirochnick, M., Michaels, M., Clarke, D., Brena, A., Regan, A. & Pelton, S. (1993). Pharmacokinetics of dapsone in children. Journal of Pediatrics, 122, 806-809.
12. Pasvol, G., Newton, C. R. J. C., Winstanley, P. A., Watkms, W. M., Peshu, N. M., Were, J. B. O., Marsh, K. & Warrell, D. A. (1992). Quinine treatment of severe falciparum malaria in African children; a randomized trial of three regimens. American Journal of Tropical Medicine and Hygiene, 45, 702-713.
13. Petersen, E., Flachs, H., Hogh, B., Hanson, A. P., Björkman, A. & Hvidberg, E. F. (1990). Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses. Journal of Tropical Medicine and Hygiene, 94, 199-205.
14. Phillips-Howard, P. A. & Björkman, A. (1990). Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs. Bulletin of the World Health Organization, 68, 493-504.
15. Radloff, P. D., Phillips, J., Nkeyi, M., Hutchinson, D. & Kremsner, P. G. (1996). Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet, 347, 1511-1514.
16. Rowland, M. & Tozer, T. N. (1995). Clinical Pharmacokinetics: Concepts and Applications. Baltimore etc.:Williams & Wilkins.
17. Sudre, P., Breman, J. G., McFarland, D. & Koplan, J. P. (1992). Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis. International Journal of Epidemiology, 21, 146-154.
18. Trigg, J. K., Mbwana, H., Chambo, O., Hills, E., Curtis, J., Issifou, S., Durasingh, M. & Curtis, C. F. (1996). Resistance in Tanzanian Plasmodium falciparum to pyrimethamine-sulfadoxine and a test of chlorproguanil-dapsone. Annals of Tropical Medicine and Parasitology, 90, 408 (abstract).
19. Veenendaal, J. R., Edstein, M. D. & Rieckmann, K. H. (1988). Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine®. Chemotherapy, 34, 275-283.
20. Ward, S. A., Watkins, W. M. & Mberu, E. (1989). Intersubject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. British Journal of Clinical Pharmacology, 27, 781-7'87.
21. Watkins, W. M. & Mosobo, M. (1993). Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 75-78.
22. Watkins, W. M., Chulay, J. D., Sixsmith, D. G., Spencer, H. C. & Howells, R. E. (1987). A preliminary pharmacokinetic study of the antimalarial drugs proguanil and chlorproguanil. Journal of Pharmacy and Pharmacology, 39, 261-269.
23. Watkins, W. M., Brandling-Bennett, A. D., Nevill, C. G., Carter, J. Y., Boriga, D. A., Howells, R. E. & Koech, D. K. (1988). Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 398-403.
24. WHO (1990). Severe and complicated malaria, 2nd edition. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, supplement 2.
25. WHO (1995). Twelfth Programme Report of the UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR). Geneva: World Health Organization.
26. Winstanley, P. A. (1996). Pyronaridine-a promising drug for Africa? Lancet, 347, 2-3.
27. Winstanley, P. A., Watkins, W. M., Newton, C. R. J. C., Nevill, C., Mberu, E., Warn, P. A., Waruiru, C. M., Mwangi, I. N., Warrell, D. A. & Marsh, K. (1992). The disposition of oral and intramuscular pyrimethamine/sulfadoxine in Kenyan children with high parasitaemia but clinical non-severe falciparum malaria. British Journal of Clinical Pharmacology, 33, 143-148.
28. Winstanley, P., Newton, C., Watkins, W., Mberu, E., Ward, S., Warn, P., Mwangi, I., Waruiru, C., Pasvol, G., Warrell, D. & Marsh, K. (1993). Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 201-206.
29. Winstanley, P. A., Mberu, E. K., Szwandt, I. S. F., Breckenridge, A. M. & Watkins, W M. (1995). The in vitro activity of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte colony-forming-units. Antimicrobial Agents and Chemotherapy, 39, 948-952.
30. Zuidema, J., Hilbers-Modderman, E. & Merkus, F. (1986). Clinical pharmacokinetics of dapsone. Clinical Pharmacokinetics, 11, 299-315.